Is China Biopharma Hollowing Out US Innovation? | Tess Cameron, RA Capital

Welcome to Episode 2 of BIO & Beyond: China Biopharma Goes Global — an interview series that asks one question across the whole industry: What will it take for China’s innovation to compete globally? You will hear the answer from the founders building the science, the global pharma buyers deciding what clears the bar, the enabling partners making molecules developable anywhere, and the investors underwriting the shift. In this episode, PharmCube speaks with Tess Cameron, Managing Director at RA Capital. Drawing from her extensive experience in corporate strategy, company building, and venture capital, Tess shares how RA Capital views cross-border assets, clinical trial execution in China, and the reality of global biotech dealmaking. Timestamps: 00:00 - Introduction & Tess Cameron’s Background 01:42 - On the Ground in Shanghai: The Pace of Local Innovation 03:26 - Incremental vs. True Innovation: "Unconscionable to Deny" 07:41 - Societal Value & Generalised Cost-Effectiveness Analysis 10:13 - RA Capital's "Swift Bridge": Integrating China Clinical Speed 14:30 - Evaluating Data Quality & Regulatory Acceptance 16:59 - Are China Licensing Deals Hollowing Out US Biotech? 22:24 - The Future of Cross-Border Collaboration 🔔 Subscribe to PharmCube for more high-level market intelligence and executive interviews! 🔗 Connect with us: LinkedIn: linkedin.com/company/cnpharmcube/ Website: https://global.pharmcube.com/